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INTRODUCTION 
Head and Neck Squamous Cell Carcinoma (HNSCC) include squamous 
epithelial cancers of the upper aerodigestive tract. HNSCCS represent the sixth most 
common cancer in the world, and accounts for more than 500,000 new cases annually 
[1]. HNSCC, especially oral cancers have a multifaceted aetiology. A plethora of 
lifestyle, environmental, viral and genetic factors has been identified as the risk factor 
for oral cancers. However, smoking, tobacco chewing, and alcohol consumption are 
widely considered to be major preventable risk factors. [2, 3] 
 Effective treatment regimens with advanced surgical procedures and new 
radiotherapy techniques have resulted in improvements in the survival and quality of 
life of oral cancer patients. However, overall 5 year survival is still around sixty 
percent. Most patients present with advanced disease and hence poor prognosis. [4] 
The inherent genetic and phenotypic heterogeneity and scarcity of good 
molecular targets have hampered the development of targeted agents for HNSCC. A 
deeper understanding of the genetic factors and molecular mechanisms of 
carcinogenesis involved in HNSCC is required for the discovery of new bio markers 
that can be used for early detection and treatment. This is especially important in the 
present era where the emphasis is on early detection, prevention and organ-preserving 
treatment protocols. [5] 
A number of high quality genomics-based researches in the recent times have 
unravelled different types of genetic alterations associated with these tumours. Also, 
new, innovative and highly accurate technologies have led to the detection of new 
biomarkers in HNSCC.  
A new class of small non coding RNAs termed as microRNAs (miRNAs) have 
recently been identified as potential biomarkers in various cancers. These miRNAs 
are endogenous, small, non coding RNAs of 17–25 nucleotides size. They are thought 
to be involved in many essential biological functions of the cell like cellular 
differentiation, proliferation, development, apoptosis, cell cycle regulation, etc. by 
regulating the genes at the post transcriptional level. MiRNAs may play a crucial role 
in tumourigenesis by differential expression in cancer cells when compared with 
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noncancerous normal cells. Studies about the role of miRNAs’ varied expressions in 
the diagnosis and prognosis of cancers have been reported. Few of these studies have 
shown strong clinical benefits of using miRNA expression profiles to warrant further 
investigation. [6] 
Microarray analysis is the most prevalent technique of miRNA expression 
profiling. Consistently altered miRNA expressions (up/down regulation) have been 
demonstrated by various groups in oral squamous cell carcinomas. The aim of such 
expressional analysis studies is to identify potential miRNA candidates that may aid 
in the diagnosis, treatment and predict clinical outcomes of oral cancers. [6] 
In this study, we intended to analyze the possible clinical roles that miRNA 
expression profiles may play in oral cancer patients. 
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REVIEW OF LITERATURE 
Oral cancers – Introduction 
Head and Neck Squamous Cell Carcinoma (HNSCC) includes epithelial cancers 
of the upper aerodigestive tract and ranks as the sixth most common cancer in the 
world. It accounts for more than 500000 new cases annually [1].The majority of oral 
cavity cancers (approx. 90%) are squamous cell carcinomas (SCC). The oral 
cavity includes the following sub sites (Figure 1): 
• Anterior two thirds of the tongue 
• Gingiva and alveolus 
• The buccal mucosa 
• Floor of the mouth under the tongue 
• Hard palate 
• Retro molar   
• Upper and Lower Lips 
Signs and Symptoms of oral cancers include: 
• Pre malignant lesions: 
 White patches (leukoplakia)  
 Mixed red and white patches (erythroleukoplakia)  
 Red patches (erythroplakia)  
• Ulcers 
• Lumps 
• Bleeding 
• Loose teeth 
• Dysphagia/ Odynophagia 
• Trismus 
• Akyloglossia 
• Neck swelling 
• Earache 
  
  MiRNAs Expression in Oral Cancers  
4 
 
Figure 1: Oral Cavity Sub sites 
 
 
Figure 2: Incidence and 5 Year Survival of Oral Cancers (SEER Statistics) 
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Epidemiology of Oral Cancers: 
Head and Neck cancers, especially oral cancers are a one of the most common 
cancers by incidence and cancer related mortality. An estimated 263,900 new oral 
cavity cancer (including lip cancer) cases and 128,000 deaths occurred worldwide in 
2008. [1] The incidences of head and neck cancers are higher in developing countries 
than in developed countries. Oral cancers are the second leading cancer by incidence 
and cancer related mortality in South Central Asia (including India). The highest 
incidences of oral cavity cancer are in South-Central Asia, Central and Eastern 
Europe. The incidence is lowest in Africa, Central America and Eastern Asia.  [2] 
The increase in incidence of oral cancers among females in the west in recent 
years probably reflects the consequences of the upsurge in the tobacco epidemic. On 
the other hand, there is a decrease in oral cavity cancer trends for all ages and both 
sexes in places where the tobacco epidemic ended prematurely. Oral cancer is a 
disease of the elderly and most of the cases of occur in 50 - 70 years age group.  
Recently, there has been a shift towards younger age at diagnosis; about 17% of 
patients are below 40 years. Considering all the age groups, men are more affected 
than women.  [2] 
The commonest sub site depends on the predominant risk factors in that 
particular geographical region. The incidence of oral cancer sites related to HPV 
infections are increasing in young adults in the United States and Europe due to 
changes in sexual behaviour. [1] In South East Asia, Japan, India and Iran tongue is 
the common sub site (up to 42%) of all oral cancers of all ages. In India, tongue and 
buccal mucosa are the most common sub sites. Buccal mucosa cancers are also 
common in Pakistan and Taiwan. Lip cancers are less common in Asian countries. 
Tongue is also the commonest sub site in young adults (45 years or below). Older 
people have tendency to develop cancer of buccal mucosa.  [2] 
Overall 5 year survival rates vary between 37 and 62 percent in oral cancers. 
Oral cavity cancer death rates have shown varied trends across the globe with a 
decline in Asian and European males but increase in some eastern European 
countries and females. 
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Risk Factors:  
Smoking, smokeless tobacco products (quid), alcohol and HPV infections are 
the major risk factors for oral cavity cancer. Smoking and alcohol have shown to 
have synergistic effects. Globally smoking (42 %) and heavy alcohol consumption 
(16%) account for majority of deaths due to oral and pharyngeal cancers. Smokeless 
tobacco products and betel nut quid are the major risk factors in the Indian 
subcontinent and South East Asia. [2] 
Premalignant lesions for oral cancers are 
• White patches (leukoplakia) 
• Red patches (erythroplakia) 
• Mixed red and white patches (erythroleukoplakia or "speckled leukoplakia") 
• Oral lichen planus  
• Oral sub mucous Fibrosis 
• Actinic cheilitis.  
In the Indian subcontinent, due to betel and tobacco quid chewing oral sub 
mucous fibrosis is very common. It is characterized by limitation of mouth opening 
(Trismus) and burning sensation on eating of spicy food. It is a progressive lesion 
sometimes leading to complete trismus. Infection with human papillomavirus (HPV), 
particularly HPV-16 and HPV – 18 is a known independent causative factors for oral 
cancer especially in young adults who are non tobacco users. HPV16 and HPV18 are 
also associated with cervical cancers. The common sub site in HPV related cancers is 
the oropharynx (tonsils, tonsillar pillars, base of the tongue). These tumours also 
respond better to radiation treatments than tobacco aetiology disease and have a 
better survival rate. [7]  
Hematopoietic stem cell transplantation (HSCT) is also a risk factor in oral 
cancers. These tumours generally have a more aggressive behaviour with poorer 
prognosis, when compared to oral cancer from other causes. The probable reason for 
such aggressive behaviour may be the lifelong immune suppression and chronic 
oral graft-versus-host disease [8]  
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Diagnosis and Staging [9] 
Diagnosis of oral cancers include 
• Clinical examination of the oral cavity 
• Imaging 
o Dental X-rays – Pan odantogram 
o Chest X-rays 
o CT/ MRI scan of Face and Neck 
o Ultrasound Scan of Neck  
o PET Scan 
• Tissue biopsy 
o A non-invasive brush biopsy (BrushTest)  
o Punch biopsy / Incision Biopsy / Excision Biopsy 
o FNAC of Neck Nodes 
Oral Cancers are staged using the TNM /AJCC Cancer Staging System (7th Edition). 
(Figure 3) [9] 
Management [9] 
 The management options for oral cancers include surgery, radiotherapy and 
chemotherapy. Surgery is the preferred treatment option for most early cancers 
whereas multimodal approach using a combination of radiotherapy, chemotherapy 
and surgery is used for most advanced cancers. Surgical options vary according to the 
sub site and include: 
• Maxillectomy (partial, subtotal, total with or without orbital exenteration) 
• Mandibulectomy (Hemi, marginal, posterior etc) 
• Glossectomy (total, subtotal, hemi or partial) 
• Neck dissections (Selective/comprehensive) 
• Wide Excision  
• Moh's procedure 
• Combinational e.g. Composite Resections 
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• Feeding tubes for nutrition. 
Reconstruction of the soft tissue and bony defects can be done by  
• Primary Closure 
• Skin Grafts 
• Local Flaps e.g. Deltopectoral, pectoralis major, nasolabial, submental, 
forehead, etc 
• Free Flaps e.g. Radial forearm, anterolateral thigh, latismus dorsi, etc 
Radiotherapy includes external beam radiotherapy and brachytherapy 
(implants, coils, moulds, etc) and can be given in the neoadjuvant setting (i.e., before 
surgery, the primary mode of treatment) or adjuvant setting (after definitive surgery) 
usually in combination with chemotherapy. The primary and the neck nodes are 
irradiated. Treatment planning including target delineation and optimal dose 
distribution is done based on the disease stage, extent of involvement, differentiation, 
patient characteristics, etc and requires good head and neck imaging. The usual 
radiation dose is 66-74 Gy to gross disease, 50-60 Gy to subclinical disease and 37.5 -
50 Gy for palliation. 
Common chemotherapy agents used in oral cancers are combination of 
cisplatin, 5 fluorouracil, paclitaxel, bleomycin and targeted agents like cetuximab. 
Chemotherapy is used alone or concurrently in the neoadjuvant, adjuvant and 
palliative settings. The NCCN guidelines for the treatment of early and advanced oral 
cancers are shown in figures 4 to 9. [9] 
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Figure 3: Oral Cancer Staging (AJCC/TNM 7th Edition) 
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Figure 4: Treatment of Early oral cancers: 
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Figure 5: Treatment of Advanced Oral Cancers  
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Figure 6: Treatment of Very advanced Oral Cancers 
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Figure 8: Treatment of Recurrent/ Persistent Oral Cancers 
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Figure 9: Treatment of Distant Metastases: 
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Cell Structure and Cell Cycle 
 The cell is the basic functional and structural unit of all organisms. Growth, 
development, differentiation, aging, disease, death and all other physiological 
processes can be described at the cellular level. The cell consists of cell membrane, 
cell wall, cytoplasm, various cellular organelles like cytoplasmic reticulum, Golgi 
bodies, mitochondria, ribosomes, vesicles, etc and nucleus (Figure 10). The normal 
cell cycle is shown in Figure 11. 
Nucleic acids (DNA and RNA) 
The two main genetic materials in all cells are Deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA) (Figure 12).  DNA is used for encoding and storage of 
long-term biological information. RNA is used to transport and transform the 
information encoded in the DNA into various proteins for cellular function. The DNA 
and RNA have similar chemical structures with some exceptions.  
DNA RNA 
Double Stranded Single Stranded 
Sugar Moiety– Deoxyribose Sugar Moiety- Ribose 
Adenine: Thymine Base pairing Adenine:Uracil Base Pairing  
Long Chain/ circular Shorter Chains 
Stable Easily Prone to Hydrolysis and Degeneration 
Ribonucleic Acid (RNA) 
There are several types of RNA, each with its unique functions. Most 
biologically active RNAs contain self-complementary sequences to fold and form 
double helices like DNA. However, the RNA double helices are shorter helices than 
that found in the DNA. The enzymatic property of the RNA is due to these helical 
structures. 
Transcription is the process by which RNA is synthesized using DNA as a 
template. The enzyme RNA polymerase catalyzes RNA synthesis. Transcription of 
RNA consists of the following steps: Initiation, Elongation and Termination.   
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Initiation of transcription begins with binding of RNA Polymerase enzyme to 
a promoter sequence in the DNA. Its helicase activity first unwinds the DNA double 
helix.  Then synthesis and elongation of complementary RNA sequence occurs from 
the start codons, in the 5’ to 3’ direction as the RNA polymerase enzyme progresses 
along the opposite direction. Thus the RNA sequence is dictated by the DNA template 
sequence. Termination occurs at stop codons in the DNA. Primary transcript RNAs, 
called pre mRNA are further modified by the addition of a poly (A) tail and a 5' cap in 
eukaryotic cells. The introns are removed by enzymes called the spliceosomes.[10] 
Types of RNA  
RNAs can be classified according to their structure and function. A modified 
list of various types of RNA is shown in Table 1[11] 
Micro RNA 
Micro RNAs (miRNAs) are small non coding RNAs of approximately 18 to 
22 nucleotides size. They have been found in both plants and animal cells and are a 
novel class of gene regulators. The first miRNA was described in 1993 in C. elegans. 
[12] 
The expression of miRNA is highly heterogeneous. Different miRNAs are 
expressed in different cell types and tissues. MiRNAs are also found to be 
highly conserved in eukaryotic cell evolution.  More than clinically relevant 530 
miRNAs have been identified in humans. Details about all known miRNA are 
available in as a searchable database called miRbase which is maintained by the 
University of Manchester, United Kingdom.  It is predicted that miRNAs regulate 
expression of 30-60% of human genes. Recent evidences also indicate that miRNAs 
may have a significant role in cancerigenesis by functioning as tumour suppressors 
and oncogenes. Such miRNAs with a role in cancer are called as oncogenic miRNAs 
(oncomiRs). [13-16] 
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Figure 10: Cell Structure  
 
Figure 11: Human Cell Cycle  
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Figure 12: DNA and RNA 
 
Figure 13: RNA Transcription 
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Table 1: Classification of RNA 
Type Abbreviation Function Distribution 
RNAs involved in protein synthesis 
Messenger RNA mRNA Codes for protein All organisms 
Ribosomal RNA rRNA Translation All organisms 
Signal recognition particle RNA 7SL RNA or SRP RNA Membrane integration All organisms 
Transfer RNA tRNA Translation All organisms 
Transfer-messenger RNA tmRNA Rescuing stalled ribosomes Bacteria 
RNAs involved in DNA replication & post-transcriptional modification 
Small nuclear RNA/ Small 
nucleolar RNA 
snRNA/ snoRNA 
Splicing and other functions, Nucleotide 
modification of RNAs 
Eukaryotes and archaea 
SmY RNA SmY mRNA trans-splicing Nematodes 
Guide RNA gRNA mRNA nucleotide modification Kinetoplastid mitochondria 
Ribonuclease P/MRP RNase P/MRP 
tRNA maturation/ rRNA maturation, DNA 
replication 
All organisms, Eukaryotes 
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Type Abbreviation Function Distribution 
Y RNA 
 
RNA processing, DNA replication Animals 
Telomerase RNA 
 
Telomere synthesis Most eukaryotes 
Regulatory RNAs 
Antisense RNA aRNA 
Transcriptional attenuation / mRNA degradation 
/ mRNA stabilisation / Translation block 
All organisms 
Long noncoding RNA Long ncRNA Various Eukaryotes 
MicroRNA miRNA Gene regulation Most eukaryotes 
Small interfering RNA siRNA Gene regulation Most eukaryotes 
Repeat associated siRNA rasiRNA Type of piRNA; transposon defense Drosophila 
Parasitic RNAs 
Retrotransposon Self-propagating Eukaryotes and some bacteria Eukaryotes and some bacteria 
Viral genome Information carrier 
ds RNA viruses, RT viruses, other  
RNA viruses 
ds RNA viruses, RT viruses, other  RNA 
viruses 
Viroid Self-propagating Infected plants Infected plants 
Satellite RNA Self-propagating Infected cells Infected cells 
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Synthesis of miRNA 
The biogenesis of miRNA is similar to that of other RNAs. Pri-miRNA 
transcripts are produced in the nucleus by RNA Polymerase II (Pol II). This pri-
miRNA is processed by the RNase III enzyme Drosha and its co-factor Pasha, to form 
the pre-miRNA precursor, which is then transported to the cytoplasm.  Another 
RNase called Dicer processes this pre-miRNA to form a miRNA: miRNA duplex. 
This duplex is stored in the miRNA-associated multi protein RNA-induced silencing 
complex (miRISC) and mature single-stranded miRNA is released when needed.  
(Figure 14) [14] 
Mechanisms of Action of miRNA 
MiRNAs play a role in the regulation of cell development, differentiation, 
proliferation and apoptosis. MiRNAs regulate their targets in two ways. The method 
of regulation depends on complementarities between the miRNA and its target. Both 
methods leads to negative regulation (Figure 14). [14, 15] 
1. RNA mediation interference Pathway (RNAi):  
MiRNAs binding to targets with perfect or near perfect complementarities cause 
cleavage of the target mRNA. Such target sites for miRNAare generally found in 
the coding sequences or open reading frame (ORF) of the target mRNA. 
2. Post transcriptional Repression of target Gene:  
MiRNAs binding to targets with imperfect complementarities cause post 
transcriptional block of target gene expression at protein translation level. Such 
target sites are generally found in the 3′ untranslated regions (3’ UTRs) of the 
target mRNA genes. 
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Nine mechanisms of miRNA action are described: 
 
Role of miRNAs in cancers 
MicroRNAs can function both as tumour suppressors and oncogenes 
depending on their target gene (Figure 15). In normal cells with normal miRNA levels 
causes repression of target-gene expression through a block in protein translation or 
altered mRNA stability. The overall result is normal cell growth, proliferation, 
differentiation and cell death. [14] 
The down regulation of a miRNA that functions as a tumour suppressor and 
amplification or over expression (up regulation) of a miRNA that functions as an 
oncogene leads to inappropriate expression of the target oncoprotein.  The overall 
result is increased proliferation, invasiveness, angiogenesis, decreased apoptosis, de-
differentiation, etc ultimately leading to tumour formation. Down regulation can occur 
because of defects at any stage of miRNA biogenesis. Increased miRNA levels may 
be due to miRNA gene amplification, constitutively active promoter region, increased 
efficacy of miRNA processing, increased stability of mRNA/miRNA, etc. Oncogenic 
miRNAs can be classified based to their function, target gene, up/down regulation; 
causal / non causal, etc. Table 3 lists commonly identified oncomiRs. [16] 
Up or down-regulation of miRNAs observed in tumours does not necessarily 
indicate its causative role in tumourigenesis. It may be a secondary event due to loss 
of normal cell function and malignant change. To define the miRNAs as tumour 
suppressor or oncogene, four evidences must be provided:  
1. Widespread deregulation (Up/down regulation) in diverse cancers  
During Transcription
• 40S  Cap initiation
• 60S Ribosomal unit joining
• Elongation 
• Ribosome drop-off (premature 
termination)
Post Transcription
• Degradation of nascent protein 
during translation
• Sequestration in P-bodies
• mRNA Decay (destabilisation)
• mRNA Cleavage
• Chromatin reorganization
• Gene silencing
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2. Gain or loss of function of the miRNA in the tumour cells 
3. Evidence for tumour-suppressor/ oncogenic activity in animal models  
4. Identification and verification of cancer related targets through which these 
miRNAs acts in oncogenesis.  
Table 3: miRNAs Profiles in common cancers 
 
MiRNAs expression patterns are highly specific to cell-type and 
differentiation status. Some microRNAs reported to be up-regulated in one type of 
cancer may be down-regulated in other cancers. For some miRNAs, both up- and 
down-regulation have been reported in the same cancer type by different studies.  
Techniques of miRNAs Expression Profiling 
Microarray analysis is the most common high-throughput technique used for 
assessment of cancer-specific miRNA expression levels in a large number of samples. 
Other techniques include bead-based flow cytometry, quantitative real-time PCR, 
miRAGE, RAKE assay, etc. Each of these techniques has its strengths and 
weaknesses (Table 4, Figures 16, 17). Usually, the first step in miRNA studies is 
isolation of total RNA and enrichment or direct isolation of small RNAs. The 
miRNAs are then labelled, cleaned-up, assessed for quality and then hybridized to 
arrays spotted with miRNA probes. After several washes the differential miRNAs are 
identified by scanning. 
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Figure 14: Biogenesis, Structure and Mechanism of Action of miRNA 
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Figure 15: miRNAs Role in tumourigenesis 
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Validation following microarray studies is done using Northern blot, 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR), or other 
analytical methods. Recent developments in labelling methods and microarray probe 
designs enable study of as low as 120 ng of total RNA without fractionation or 
amplification, to produce precise and accurate measurements of 0.2 amol to 2 fmol of 
miRNA. [17] 
Table 4: miRNAs Profiling methods 
 
MiRNAs and Oral Cancers 
 MiRNAs have tremendous potential as a new class of molecular tumour 
biomarker. The diversity in their expression across human cancers can provide a large 
amount of diagnostic, prognostic, and predictive information. The list of commonly 
deregulated miRNAs in oral cancers and their proposed targets are given in Tables 5 
& 6. [6, 18-21] 
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Table 5: Common miRNAs deregulated in oral cancers 
 
MicroRNA 125b (miR 125b) 
miR 125b is known to have altered expression in oral cancers. Its target genes 
are KLF13 (down-regulated), CXCL11 and FOXA1 (both up-regulated). KLF13 is a 
transcription factor involved in proliferation and differentiation of cardiac cells, B-and 
T-cell. CXL11 is a chemokine and a ligand for CXCR3 involved in immunity, 
inflammation and angiostasis. FOXA1 a transcription factor involved in both growth 
stimulation and repression. [19] 
MicroRNA 21 (miR 21) 
MiRNA-21 is one of the most consistently deregulated miRNAs in many 
cancers. It is well established oncogenes. It has been demonstrated to promote cell 
proliferation and suppresses apoptosis. It regulates tropomyosin 1 (TPM1), 
programmed cell death 4 (PDCD4), PTEN (phosphatase tensin homologue) and 
mapsin. In one study, inhibition of miR-21 in tongue cancer cell lines reduced 
survival, anchorage dependant growth and induced apoptosis. It has been also found 
to be an independent prognosticator of poor survival for tongue cancers. [19] 
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MicroRNA 138 (miR 138) 
Reduced miR-138 expressions have been shown to be associated with 
enhanced metastatic potential in oral cancers. This involves suppression of the Rho 
GTPase signalling cascade. The Rho GTPase cascade acts as molecular switch that 
regulates cell shape, polarity and locomotion by acting on intracellular actin (Figure 
18). [19] 
MicroRNA 184 (miR 184) 
miR 184 is deregulated in tongue cancers. It is postulated that miR-184 acts as 
an oncogene by targeting C-MYC gene and induces proliferation and inhibiting 
apoptosis. [19] 
Recent studies have shown that specific miRNAs expression signatures are 
correlated with prognosis and clinical aggressiveness. Identification of miRNAs 
alterations in oral cancers could facilitate our understanding and guide targeted 
therapy. Table 7 lists the recent studies in miRNAs deregulated in oral cancer. 
Pharmacological modulation of miRNAs expressions leading to ‘‘normalization’’ of 
malignant phenotypes is a potential approach in cancer treatment.  The combination 
of miRNAs targeting with classical chemotherapy or radiation therapy may provide 
new tools against cancer. [20-30] 
Against this background, we intended to study the feasibility of extracting 
miRNAs from oral cancer tissue samples on a real time basis and to study the clinical 
role of selected miRNAs expression profiles. 
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Figure 16: Microarray and Bead Based Techniques 
 
Figure 17: RT PCR Technique 
 
Figure 18: Proposed role of miR -138 in oral cancers 
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Table 6: Common Oral Cancer deregulated miRNAs and their targets [20, 21] 
microRNA Proposed Target gene(s) 
microRNA-184  C-MYC 
micrRNA-133a /133b PKM2 (pyruvate kinase type 2) 
microRNa-137 and 193a CDK6 (cyclin dependant kinase 6), E2F transcription factor 6, DNA hypermethylation 
microRNA-15a Cyclin E, PKCa (protien kinase c alpha) down regulates microRNA-15a that directly inhibits cyclin E 
microRNA-21 TPM1 and PTEN (tropomyosin 1 and phosphatase tensin) 
microRNA-103 and 107 PDCD4 (programmed cell death protein 4), TGFBR3 (tumour growth factor receptor beta 3) 
microRNA-205 and let-7 DHFR (dehydrofolate reductase) 
microRNA-125b and100 KLF13, CXCL11 and FOXA1, EGFR3 (epidermoid growth factor receptor 3) 
microRNA-222 MMP1 (matrix metalloproteinase 1) , SOD2 (manganese superoxide dismutase 2) 
microRNA-24 DND1 (dead end 1)   
microRNA-7 IGF1 R (insulin-like growth factor1 receptor) 
microRNA-138 GNAI 2 (G protein alpha inhibiting activity polypeptide 2) 
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Table 7: Recent Studies on miRNA in oral cancers [Ref 20-30]. 
Study miRNAs Tumour Samples Comments 
Tran et al 2007 
23 miRNAs ↑ - miR 21,16,let 7,205 
22 miRNAs ↓  
9 cell lines 
No controls. First study to do genome wide 
survey of miR in HNSCC 
Chang et al 2008 
8 miR ↑- miR 21,18,19,29c,155,let 7 
1 miR ↓- miR 494 
4 cell lines, 4 tumour samples & 4 
normal controls 
Used control samples 
Wong et al 2008 
24 miR↑ - miR 184,21 
13 miR↓ - miR 100,125,133 
4 cell lines, 4 tumour samples, 4 
normal controls 
Used paired controls 
Kozaki et al 2008 
11 miR↑ - 374,224,31,9,340 
54 miR↓ - miR 137,139,133,138 
18 cell lines 
11 primary frozen tumour samples 
Control - Immortalized keratinocyte line RT 17  
Avissur et al 
2009 
11 miR ↑- miR 21 
1 miR ↓- miR 375 
16 fresh frozen tumour samples 
5 normal epithelial tissues, 2 cell 
lines 
 
Ramdas et al 
2009 
16 miR↑ - miR-21,34b,155, 
182,185,let7,15b,7 
4 miR↓- 23b,125a,125b 
5 tumour samples and  
adjacent normal tissue controls 
Demonstrated that tumour and adjacent normal 
tissue can be differentiated based on miRNA 
differential expression 
Scapoli et al 2010 
13 miR ↑ - miR21 
4 miR ↓- miR 155,146a 
15 tumour samples 
miR 146a was found to characterize disease 
progression and nodal metastasis 
Lajer et al 2011 114 miR  deregulated in oral cancers 
miR 375,31 ↑ 
51 oral and pharyngeal cancer 
samples and controls 
Showed relation between HPV infection and 
miR deregulation in pharyngeal cancers 
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AIMS OF THE STUDY 
1. To assess the feasibility of extracting miRNA in oral cancer tumour tissue samples 
2. To assess selected miRNAs expression profiles and compare it with 
epidemiological data, tumour characteristics and clinical behaviour of oral cancer 
patients  
MiRNAs Expression in Oral Cancers 
 
33 
 
STUDY DESIGN 
Study design: Prospective collaborative clinical and molecular research 
Place of Study: 1. Department of Surgical Oncology, Centre for Oncology 
Govt. Royapettah Hospital & Kilpauk Medical College, 
Chennai 
2. Department of Genetics 
Dr. ALM PG Institute of Basic Medical Sciences 
University of Madras, Taramani Campus, Chennai 
Duration of Study: October 2011 – December 2013 
Number of Patients: 36  patients with oral squamous cell carcinomas 
Inclusion criteria: 1. Patients of age 18 to 70 years  
2. Oral squamous cell carcinomas, all sub sites  
3. Patients on regular follow-up 
Exclusion criteria: 1. Metastatic disease 
2. Recurrent or second primary cancers 
3. Patients who had previously undergone any treatment for 
the primary disease 
4. Other medical illness(es) precluding full study 
participation 
Materials: 1. Clinical data of patients 
2. Tumour tissue samples from biopsies and  surgical 
specimens 
Principal 
Investigator: 
 
Prof. R. Rajaraman MS, MCh 
Professor and Head, Centre for Oncology 
Department of Surgical Oncology 
Govt. Royapettah Hospital & Kilpauk Medical College, 
Chennai 
Co Investigator: 
 
Dr. A.K. Munirajan PhD  
Professor, Department of Genetics 
Dr. ALM PG IBMS, University of Madras, Chennai  
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Figure 19: Study Design 
Patient
Clinical Data
Epidemiology
Tumour Characteristics
Clinical Behaviour
Tumour Biopsy
Selected miR Expressions
miR 125-b2, miR 21, miR 
184, miR 138
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MATERIALS AND METHODS 
This study was part of a larger research study on the role of miRNAs 
expression profiles of various cancers which is currently in progress in the 
Department of Genetics, Dr. ALM PGIMS, University of Madras. 
 Patients diagnosed with oral cancers fitting the inclusion and exclusion 
criteria were enrolled in the study after written informed consent.  
CLINICAL DATA  
All patients underwent a complete clinical examination, dental evaluation, 
ENT evaluation and relevant radiological including Chest X-Ray and CT/MRI of 
Primary & neck and other investigations required for diagnosis and staging. 
Multidisciplinary evaluations were done as indicated. Pre-anaesthesia fitness was 
taken for patients undergoing surgery. Relevant history including smoking habits and 
other addictions, co morbidities, previous treatment and family history were obtained 
(As per Proforma).  
All patients were staged according to UICC TNM 7th edition staging system 
after histopathological proof of cancer by biopsies. Patients received treatment 
according to their cancer site and stage as per standard practice.  
PATIENT FOLLOW-UP 
 All patients were followed monthly in the first year, every 2 months in the 
second year, and every 6 months thereafter. During each follow- up, patients undergo 
complete clinical examination after relevant history to look for disease recurrence. 
Further, patients undergo yearly chest X-Ray as part of their metastatic workup and 
other investigations as and when indicated. Patients are referred for relevant 
rehabilitation programs at the end of their treatment. 
TUMOUR TISSUE SAMPLE  
Tumour tissue samples were collected as described below at the time of 
diagnosis from tumour biopsies and/or from the surgical specimens in patients who 
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undergo surgery. (Figure 1) Biopsy or surgical tissue sample (tumour tissue and 
tumour free normal tissue from margins) was collected in a storage tube with 3 ml of 
RNAlater® (Invitrogen Life Technologies, USA) solution and transferred to the 
Department of Genetics, University of Madras, Chennai in icepacks. The amount of 
tumour tissue needed for DNA/RNA studies is about 500-1000 mg.  
The tissue is then chopped to smaller pieces and stored in the same 
RNAlater® (Invitrogen Life Technologies, USA) solution at 4°C overnight. RNAlater 
prevents RNA from getting degraded during transportation and storage. After 24hrs, 
the RNAlater® (Invitrogen Life Technologies, USA) solution is drained from the tube 
and the tissue is stored at minus 20°C until isolation of RNA is done.  
RNA ISOLATION PROTOCOL 
The frozen tissues are allowed to thaw on ice and excess of RNAlater® 
(Invitrogen Life Technologies, USA) solution (or crystals if any) removed using a 
clean tissue paper and transferred to sterile 2 ml Eppendorf tubes. One ml of TRIzol® 
(Invitrogen Life Technologies, USA) and zirconium beads are added to the tissue 
sample. 
The tubes are then subjected to repeated homogenization in MicroSmash® 
MS100 (Tomy Digital Biology Co.Ltd, Japan) homogenizer at 3500 rpm for 30 
seconds with equal intervals of 1 minute incubation on ice until a clear homogenate is 
obtained. The homogenate is then transferred to a new sterile 2 ml Eppendorf tube 
and 0.2 ml of chloroform is added. The mixture is vigorously shaken for 15-30 
seconds until it turns milky. All the steps of handling the tubes after step 4 should be 
carried out on ice.  
The above mixture is centrifuged at 10,000 rpm for 20 minutes at 4°C. After 
centrifugation, three layers are formed: a clear aqueous layer, a turbid organic layer 
and an intermediate insoluble layer. The RNA containing upper aqueous layer is 
transferred to a new 1.5 ml Eppendorf tubes and 0.5 ml of cold ethanol is added and 
shaken gently to precipitate the RNA. 
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The tubes are then centrifuged again at 10,000 rpm for 20 minutes at 4°C to 
obtain a white pellet of RNA. The supernatant is discarded. To these RNA pellets, 
70% ethanol is added, mixed gently and centrifuged again at 10,000 rpm for 20 
minutes at 4°C. 
The pure RNA thus obtained is dissolved in RNAs free water and stored at 
minus 20°C. All the steps of handling the tubes after homogenization are carried out 
on ice and RNase free environment. Utmost care is taken to use RNAase free reagents 
and RNase free environment 
QUALITY VERIFICATION OF RNA 
The quality verification of RNA is carried out to ensure RNA is free from 
DNA and residual phenol/alcohol. The electrophoresis on a 0.7% agarose gel is used 
to verify the quality of RNA. 
Procedure for gel electrophoresis: 
0.7 gram of agarsose is weighed and transferred into a 250 ml conical flask. 
100 ml of 0.5x TAE buffer is added to it, stirred well and melted on a magnetic stirrer 
cum hot plate until the agars’ dissolves completely. The appropriate sized gel tray and 
comb is washed and wiped with 70% Ethanol. The gel tray is placed inside the casting 
unit. The comb is placed on the gel tray and left on an even surface. After the agarose 
cools down to hand bearing temperature, 5 µl of ethidium bromide is added and 
mixed well. It is poured on the gel tray and allowed to polymerize. After 
polymerization the comb is removed. 
The gel tray is then removed from the casting unit and placed in the 
electrophoresis tank. 0.5x TAE buffer is poured into the tank until the gel gets 
immersed.  1 µl of each RNA sample is mixed with 2μl of 6x RNA loading dye 
(formaldehyde added for denaturation of RNA) and 8ml of sterile double distilled 
water in a PCR tube. The mixture is subjected to denaturation by warming at 65˚C for 
10 min. The RNA samples are allowed to cool and loaded into the wells. The 
electrodes are connected; power set at 100 V and run for 20 minutes. 
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When bromophenol blue dye is in the middle of the gel, power is switched OFF. 
The gel is taken to the transilluminator and observed under UV light and documented. 
The good quality RNA is identified by two distinct bands (28s and 18s rRNA).  
SPECTROPHOTOMETRY 
The nucleic acid samples are analysed at 260nm and 280nm by using 
Nanodrop Spectrophotometer (Thermo scientific, Germany). The concentration and 
purity of the sample is analysed using the following formula: 
CONCENTRATION OF RNA: Concentration of double stranded RNA sample 
(μg/µl) = A260 x 40 
PURITY OF RNA: Pure RNA = A260 /A280 ≥ 2.0. The observation of absorbance 
is recorded at 280nm. 
MICRORNA EXPRESSION ANALYSIS 
The quality of the RNA was checked as mentioned above. MiRNAs 
expression profiles were studied by Real Time Quantitative Polymerase chain reaction 
(RT-qPCR) using TaqMan® MicroRNA Assays (Applied Biosystems, USA). The 
quantification of miRNA is done in two steps: 
1. Reverse transcription (RT) step:  cDNA is reverse transcribed using specific 
miRNA primers.  
2. PCR step:  the products are amplified from cDNA samples. 
TaqMan® Protocol: 
 The TaqMan® Protocol as described the supplier was used to analyze the 
miRNAs. cDNA is first synthesized from the total RNA in 15 μl reaction volumes. 
The cDNA are then first incubated at 16°C for 5 minutes to anneal the stem loop 
primer and then at 42 °C for 30 minutes. They are further incubated at 85 °C fir 10 
minutes to inactivate the enzymes. Each cDNA are then be amplified by qPCR in 20 
μl PCR reactions containing 10 μl of 2x TaqMan® Universal PCR Master Mix, 2 μl 
of 10x TaqMan® MicroRNA Assay mix and 1.5 μl of reverse transcription product. 
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The reaction are carried out under the following conditions: 95 °C for 10 minutes and 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute using sequence specific 
primers. 
Tumour tissue samples were collected from 112 patients with oral cancers 
from tissue biopsies and surgical specimens. Tissue sample from normal non 
cancerous tissues were also collected from some patients and pooled to form a control 
sample. 
 We were able to extract RNA from 76 tumour tissue samples (67.8%). Gel 
Photos and Ultraviolet Spectrometry were used to asses if the RNA was of sufficient 
quality and quantity for miRNAs Expression Studies. Of these 76 tissue samples, 52 
samples (48.2 %) had sufficient quantity and quality of RNA i.e., can be used for 
miRNAs Expression studies.  Thirty six patients with good quality RNA extracted 
from tumour biopsies were selected for miRNAs Expression Studies. MiRNAs 
Expressions of four miRNAs relevant to oral cancer based on available literature 
(miR-125b2, 184, 21 and 138) were analysed and compared with Clinical data of 
these 36 patients. Controls used were RNU 44 and RNU 48 Expression and Pooled 
Control Samples (normal tissues) 
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Figure 20: PCR System and mi RNA Assays 
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Figure 21: mi RNA Extraction Schema
 
 
Figure 22: Gel Photo of RNA 
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STATISTICAL ANALYISIS 
The miRNA expression data from tumour tissues were expressed as mean 
values and were compared with normal pooled control tissue samples and also 
normalized with external control miRNAs. Clinical data including history of smoking, 
tobacco and betel chewing and other addictions; site, stage, histological grade of 
tumour; response to treatment and survival were analyzed. Results for continuous 
variables are expressed as mean +/- standard error. Comparison of group 
characteristics was done by chi square test and analysis of variance (ANOVA). A p < 
0.05 is considered statistically significant. Statistical analysis was done using SPSS 
16® (IBM Inc, USA) and EXCEL 2007 ® (Microsoft, USA). 
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RESULTS 
Thirty six patients with good quality RNA in the tumour tissue were selected 
for miRNAs analysis. MiRNAs Expressions of four miRNAs relevant to oral cancer 
based on available literature (miR-125b2, 184, 21 and 138) were analysed and 
compared with Clinical data of these 36 patients  
Epidemiology and Tumour Characteristics: 
 Te male: female ratio was 25:11. The mean age of the patients was 51 years 
(SD±11, range: 26-70 years). Tongue (n=14, 39%) and buccal mucosa (n=8, 25%) 
were the most common sub sites. Left sided cancers were more common. Tobacco 
usage (61 %) in the form of cigarettes, beedis, smokeless tobacco like pan, etc was 
common. The other addictions seen were betel nut (27.8%), alcohol (33.3%), hans 
and cocaine. 
 Locally advanced (T4) lesions constituted 47.2 percent of all tumours and 
node positivity was seen in 70 percent of patients. Using a three grade grading system, 
44 percent of tumours were moderately differentiated and 19 percent of tumours were 
poorly differentiated. The other epidemiological details of the patients are given in 
table 8. 
Figure 23: Age Distribution of Patients 
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Table 8: Epidemiological Data and Tumour Characteristics 
 Characteristics N Percent (%) 
Sex Male 25 69.4 
Female 11 30.6 
Sub site Alveolus 5 13.9 
Buccal mucosa 9 25 
FOM 2 5.6 
Lip 1 2.8 
Palate 2 5.6 
RMT 3 8.3 
Tongue 14 38.9 
Side Left 25 69.4 
Right 11 30.6 
Tobacco  Users 22 61.1 
Non users 14 38.9 
Betel Nut Users 10 27.8 
Non users 26 72.2 
Alcohol Users 12 33.3 
Non users 24 66.7 
Other Addictions Users 5 14 
Non users 31 86 
T Stage T1 1 2.8 
T2 12 33.3 
T3 6 16.7 
T4 17 47.2 
N Stage 0 11 30.6 
1 12 33.3 
2 12 33.3 
3 1 2.8 
Grade Well Differentiated 13 36.1 
Moderately Differentiated 16 44.4 
Poorly Differentiated 7 19.4 
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Figure 24 a, b, c: Tumour Sub sites, Tumour Stage and Differentiation  
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Figure 25: Addictions 
 
Figure 26: Surgery for the Primary 
 
Figure 27: Surgery for the Neck 
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Clinical Characteristics of Patients: 
 Out of the 36 patients, 31 underwent surgery. Thirteen patients underwent 
primary surgery. Twenty two patients received neoadjuvant Chemotherapy and/or 
radiotherapy of which 5 patients had progressive disease (14%), 5 patients had stable 
disease (14%) and 12 patients had partial response. These 17 patients (PR +SD) 
underwent composite resections after neoadjuvant therapy. Another 3 patients 
received chemotherapy and/or radiotherapy adjuvantly. The details of the surgeries 
for the primary and neck nodes are shown in figures below. 
Table 9: Clinical Data of Patients: 
  N Percent (%) 
Surgery for Primary Composite Resection 1 50 
Composite Resection after Neoadjuvant 
Therapy 
17 
Hemiglossectomy 7 19.4 
Palatoalveolar Resection  1 2.8 
Wide local Excision 3 8.3 
Wide Local Excision + Marginal 
Mandibulectomy 
2 5.6 
Surgery for Neck 
Nodes 
RND 3 8.3 
MRND 21 58.3 
SOHND 7 19.4 
Chemotherapy CDDP+5FU 22 61.1 
CDDP+Taxol 3 8.3 
Radiotherapy Radical (60-66 Gy)  13 36.1 
Pre op (50 Gy) 11 30.6 
Palliative (48 Gy) 1 2.8 
Response to CRT Partial Response 12 54.5 
Stable Disease 5 22.7 
Progressive Disease 5 22.7 
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Follow up: 
With a mean follow up of 12 months (range 5-21 months), 5 patients 
developed recurrences (distant metastases to spine =2, local recurrence =1, nodal 
recurrence=2) out of whom 3 patients died during follow up. 
miRNA Expression 
 The expression of four miRNA relevant to oral squamous cell cancers were 
analysed using RT-PCR. The mean Relative Quantitification (mean RQ) of the 
miRNAs were calculated. A mean RQ ≥1.2 was taken as up regulation and mean 
RQ≤0.8 was taken as down regulation. (Table) 
Table 10: miRNA Expression 
miRNAs Up regulation 
No. of Patients 
(N) 
Normal 
No. of Patients 
(N) 
Down regulation 
No. of Patients 
(N) 
Deregulation 
(Up+ Down) 
No. of Patients 
(N) 
miR 125-b2 1 1 34 35 
miR 138 11 5 20 31 
miR 184 6 2 28 34 
miR 21 16 6 14 30 
The deregulations of these miRNAs were compared with clinical and 
epidemiological data and their P values were derived. (Table below) 
MiR 138 down regulation was seen significantly higher in younger patients 
(P=0.02, 46.6±11 years vs. 58.4±5.4 years). MiR 184 was significantly up regulated 
in non tongue cancers (P=0.035, 17 vs. 11 patients). The down regulation of 
miR125b2 in alcoholics was significantly higher when mean RQ was compared 
(P=0.02, 0.12±0.08 vs. 0.37±0.35). Similarly mean RQ values of miR 21 was 
significantly different in patients who responded to chemo radiotherapy versus non 
responders (P=0.05, 0.83±0.56 vs.1.52±0.99). Similarly miR 21 was significantly 
deregulated in left sided tumours and in high grade tumours. 
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Figure 28 a, b: miR 125b2 and 138 Deregulation 
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Figure 29 a, b: miR 184, miR 21 deregulation  
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Table 11:  miRNAs Expression vs. Clinical Characteristics (P Values) 
Clinical 
Characteristics 
miR 
125-b2 
Down 
miR 
138 
UP 
miR 
138 
Down 
miR 
184 
UP 
miR 
184 
Down 
miR 
21 
UP 
miR 21 
Down 
Sex 0.52 0.59 0.21 0.67 0.52 0.86 0.57 
Age 0.82 0.67 0.02 0.08 0.12 0.60 0.81 
Age Group:<40 
yrs vs. > 40 yrs 
0.41 0.49 0.12 0.35 0.46 0.91 0.57 
Side: left VS. 
Right  
0.13 0.54 0.31 1 0.26 0.032 0.11 
Sub site :Tongue 
vs. Others  
0.41 0.59 0.21 0.035 0.09 0.16 0.39 
T stage 0.17 0.43 0.46 0.59 0.91 0.38 0.57 
N Stage 0.52 0.44 0.97 1 0.52 0.19 0.09 
N Pos vs. N Neg 0.49 0.35 0.84 1 0.44 0.93 0.83 
Grade 0.50 0.79 0.77 051 0.8 0.59 0.04 
Tobacco 0.43 0.59 0.69 0.67 0.76 0.22 0.11 
Alcohol 0.52 0.93 0.31 0.54 0.26 0.70 0.69 
Betel 0.46 0.12 0.16 0.35 0.52 0.9 0.33 
Others 0.92 1 0.49 1 0.81 0.52 0.62 
Response to CRT 0.28 0.57 0.9 1 1 0.57 0.32 
Recurrence  0.67 0.31 0.36 1 0.51 0.25 0.33 
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DISCUSSION 
This study was a pilot study to assess the feasibility of doing miRNAs 
expression analysis in oral cancer patients. It was part of a larger ongoing project to 
assess feasibility of miRNAs expression analysis in various cancers. 
Most studies on miRNAs Expression in oral cancers are of small sample size 
based on cancer cell line cultures or few tissue samples. Also, the emphasis in these 
studies was to find out which miRNAs where unregulated or down regulated.  
 This study is probably the first study which puts the emphasis on the patient 
and analyzes whether a particular miRNAs is unregulated or down regulated in a 
particular patient. By this patient centric analysis, we intended to study whether in a 
particular patient with oral cancer, whether a single miRNAs or a panel of miRNAs, 
whose expression when elucidated in a tumour sample from the  patient, may 
probably correlate with the clinical behaviour of that patient. This in future may help 
us prepare a commercially viable miRNAs Expression analysis (either single or 
multiple) similar to gene based testing in cancers (e.g. Oncotype DX and Mammaprint 
in breast cancer). 
For this, we will first need to be able to extract miRNAs in that particular 
patient sample in sufficient quantity. The challenge for us was to safely transport and 
store the tumour samples collected at Govt. Royapettah hospital and transported and 
stored in the Dept. of Genetics, University of Madras where it was subject to further 
analysis. Unlike DNA, RNA gets degraded rapidly when removed from the body. 
Further RNAses, enzymes which degrade RNA are found ubiquitously in the 
environment from our hands to circulating air. The options available are immediate 
processing of samples, freezing the sample in liquid nitrogen to at least -20º Celsius, 
using solutions which degrade RNAses (e.g. RNAlater), etc. Immediate processing 
and freezing such large number of samples is costly and time consuming.  
We used RNAlater solution to prevent RNA degradation. We were able to 
extract RNA with good quality bands in Gel photos in 76 out 112 patients (67.8%).  
During the initial phase of the study the extraction rate was only around 40 percent 
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which improved during the second half of the study with careful avoidance of sample 
mishandling and early processing of samples.  
Most studies use microarray technique to study their expression. However 
microarray technique, though high throughput, is not a quantitative method and has to 
be validated using other techniques like northern blot or PCR. We wanted to study 
miRNAs expressions in a larger number of tumour samples. So we opted to study the 
expressions of select miRNAs based on our previous microarray data and available 
literature by quantitative RT PCR methods.  Due to cost constraints, we selected 36 
out of 52 samples with good quality RNA which were feasible for expression analysis 
for further study. We selected 4 miRNAs known to have altered expressions for our 
study i.e., miR 125b2, miR 138, miR 184 and miR 21. 
Demographic Profile of Patients 
 In our study male: female ratio was approximately 2.5:1. The mean age of 
presentation was 51 years. Tongue was the most common site followed by buccal 
mucosa and alveolus or gingiva. These data are consistent with other studies from 
India and other parts of Asia, where oral cancers are predominantly found in males in 
the 50 to 70 year age group. Tongue and Buccal mucosa are the commonest sites 
among oral cancers in Asia unlike in the west where lip cancers predominate. This is 
probably due to the etiological association with smokeless tobacco and betel nut quid 
used in this part of the world. This is also the reason for more left sided lesions in our 
study and other studies from India and other parts of Asia. 
 Tobacco usage (both smoking and smokeless tobacco) has been implicated in 
etiopathogenesis of oral cancers. Alcohol has synergistic effect with tobacco. Areca 
nut or betel nut chewing as part of a quid is common in India and south Asia and has 
been implicated in oral, especially buccal mucosal cancers. In our study, around 61 
percent of patients used some form of tobacco, one third was alcoholics and around 
27 percent used betel nut based quid. 
 In our study, nearly 50 percent of the patients had T4 (locally advanced or 
very advanced) disease and about 70 percent had neck nodal metastases. None of the 
patients had distant metastases. This data is also consistent with other studies and 
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cancer registries from India that patients with oral cancers in India present at a later 
stage than in the west.  
 Patients with early cancers underwent surgery as the primary modality of 
treatment and received adjuvant chemo radiotherapy based on histopathology. 
Patients advanced disease at presentation need multimodal management with 
chemotherapy, radiotherapy and surgery. In our study, 22 patients received 
neoadjuvant chemo and/or radiotherapy, of which 17 patients had partial response or 
no response (stable disease) and underwent further surgery and adjuvant therapy as 
appropriate based on final histopathology. Five patients had progressive disease and 
received palliative chemotherapy and/or symptomatic care. 
The advanced nature of presentation in turn leads to a dismal overall 5 year 
survival of around 37 percent in India whereas it is up to 62 percent in North 
America. In our study, 3 patients died during follow up, further 2 patients developed 
spinal metastases, two patients nodal recurrences and 1 patient had local recurrence. 
MiRNAs Expression Profiles: 
MiR 125b2 was down regulated in almost all patients (n=34). Similarly miR 
138 and 184 were also down regulated in a majority of patients. MiR 21 was up 
regulated and down regulated in almost equal number of patients. MiR 138 down 
regulation was seen significantly associated with younger age, miR 125b2 down 
regulation was significantly higher in alcoholics, miR 21 altered expression affected 
response to chemo radiotherapy, left side predominance of oral tumours and higher 
grade of tumours. MiR 184 was significantly up regulated in non tongue oral cancers.  
Some of these associations have already been shown in various studies. The 
left side predominance seen in miR 21 up regulation may probably be a spurious 
association warranting further study. One hypothesis may be due to use of quid in 
India which is usually kept on the lower gingivobuccal sulcus by patients. However, 
there was no association between miR 21 and tobacco or betel nut usage.  
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Table 12: Clinical Association of miRNAs Expressions  
miRNAs Expression  Clinical Association 
miR 125B2 ↓ Alcoholics 
miR 184 ↑ Non tongue oral cancers 
miR 138 ↓ Younger Age 
miR 21 ↓ High Grade 
↑ Left side predominance 
↑/↓ Response to CRT 
There was no association between the miRNAs studied and tumour stage, 
nodal stage, response to chemo radiotherapy, recurrence pattern, etc. the association 
between miR 21 and response to chemo radiotherapy was in the degree of altered 
expression measured by mean RQs. 
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SUMMARY AND CONCLUSIONS 
The present study was a pilot study of a patient centric analysis of the use of 
miRNAs expression profiles in the assessing clinical behaviour of oral cancer 
patients. The study included analysis of 4 select miRNAs (miR - 21, 125 b2, 184 and 
138) Expression Profiles in 36 oral cancer patients and their impact on the 
epidemiological and clinical characteristics of these patients. Based on this study the 
following conclusions can be made: 
1. The extraction and analysis of miRNAs expressions from oral cancer tumour 
tissue sample is feasible provided care in taken in transportation, storage and 
processing of the samples.  
2. MiRNAs altered expressions have definite and significant associations with 
many clinical and epidemiological characteristics of oral cancer patients. 
Development of newer, simpler, more efficient, safer and cost effective 
techniques for storage, transportation, extraction and analysis of RNA is the need of 
the hour. Further studies involving a panel of miRNAs are needed to provide 
conclusive evidences for use of miRNAs in assessing clinical behaviour of oral cancer 
patients and to influence their management. 
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PROFORMA 
 
Name:    Age:  Sex: Male / Female       Hospital ID No:
      
History: Tobacco abuse: Chewing/Smoking/None/Others 
         Duration: <5yrs/5-10yrs/>10yrs 
Alcohol abuse: Yes/No   
Duration :< 5yrs/5-10yrs/>10yrs 
Other Addictions: Yes/No   Name if any: 
Duration :< 5yrs/5-10yrs/>10yrs 
 
Primary Tumor Site: 
 
Stage (TNM 7th edition):  T N        M   Clinical/Pathological 
 
Tumor Grade:  I II III IV UNKNOWN 
 
Samples Collected:       Date 
1. At Diagnosis:  Tumor tissue/Normal tissue   
2. Post Chemo/RT:  Tumor tissue/Normal tissue  
3. At Surgery:   Tumor tissue/Normal tissue   
Treatment Given:  
1. Chemotherapy: 
2. Radiotherapy: 
3. Surgery: 
 
Follow-up Record: 
 
Date 
Follow- up 
Period 
Follow up Details and Status 
(NED/Local Recurrence/New Cancer/Distant Disease/Death/LOFU) 
   
   
   
 
 
Written Informed Consent 
   
 I …………………………….. Hereby agree to participate in the study on 
microRNA expression profiles in head and neck cancers and agree to provide my 
Tumor/ Blood samples. I have been clearly explained about the procedure and have 
been explained well about the study in my own language. I have also been told that I 
could withdraw from the study at any time and I hereby declare that all my questions 
have been clarified. 
 
 
       Signature/Thumb Impression  
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